Orexin: Clinical and therapeutic implications;Orexina: Implicaciones clínicas y terapéuticas

Revista de Neurologia

Volumn 58, Issue 3, 2014, Pages 117-124

  Mediavilla, Cristina ^a   Risco, Severiano ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Drug addiction; Lateral hypothalamus; Narcolepsy; Obesity; Orexin

Indexed keywords

OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR;

BRAIN STEM; CLINICAL FEATURE; DRINKING; EMOTION; HOMEOSTASIS; HYPOTHALAMUS; LEARNING; LIMBIC CORTEX; NERVE FIBER; OBESITY; REVIEW; SLEEP WAKING CYCLE; TASTE;

ANIMALS; AROUSAL; AZEPINES; BENZOXAZOLES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EATING DISORDERS; FEEDING BEHAVIOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR ACTIVITY; NARCOLEPSY; NEUROPEPTIDES; OBESITY; OREXIN RECEPTORS; SLEEP DISORDERS, CIRCADIAN RHYTHM; SLEEP DISORDERS, INTRINSIC; SUBSTANCE-RELATED DISORDERS; TRIAZOLES; UREA;

EID: 84893395582     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5803.2013349     Document Type: Review

References (60)

1. De Lecea L, Kilduf TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. Te hypocretins: hypothalamus-specifc peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-7.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour. Cell 1998; 92: 573-85.
3. Peyron C, Tighe DK, Van den Pol AN, De Lecea L, Heller HC, Sutclif JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
4. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res 1999; 827: 243-60.
5. Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 2013; 7: 28.
6. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011; 51: 243-66.
7. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, et al. Functional magnetic resonance imaging reveals diferent neural substrates for the efects of orexin-1 and orexin-2 receptor antagonist. PLoS One 2011; 6: e16406.
8. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, et al. Diferential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25.
9. Alexandre C, Andermann ML, Scammell TE. Control of arousal by the orexin neurons. Curr Opin Neurobiol 2013; 23: 752-9.
10. Garzón M. El sistema de neurotransmisión hipocretinérgico/orexinérgico en la regulación de los estados de vigilia y sueño. Rev Neurol 2007; 45: 482-90.
11. Sakurai T. Te neural circuits of orexin (hypocretin): maintaining sleep and wakefulness. Nature Rev Neurosci 2007; 8: 171-81.
12. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, et al. Fos expression in orexin neurons varies with behavioural state. J Neurosci 2001; 21: 1656-62.
13. Tsunematsu T, Tabuchi S, Tanaka KF, Boyden E, Tominaga M, Yamanaka A. Long-lasting silencing of orexin/hypocretin neurons using archaerhodopsin induces slow-wave sleep in mice. Behav Brain Res 2013; May 21. [Epub ahead of print].
14. Yoshida K, McCormack S, España RA, Crocker A, Scammell TE. Aferents to the orexin neurons of the rat brain. J Comp Neurol 2006; 494: 845-61.
15. Saper CB, Chou TC, Scammell TE. Te sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24: 726-31.
16. De Vicente Álvarez-Manzanera EE. Avances en el diagnóstico y tratamiento del síndrome de narcolepsia-cataplejía. Rev Neurol 2008; 46: 550-6.
17. Santamaría-Cano J. Actualización diagnóstica y terapéutica en narcolepsia. Rev Neurol 2012; 54 (Supl 3): S25-30.
18. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
19. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345-54.
20. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. Te sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.
21. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) defciency in human narcolepsy. Lancet 2000; 355: 39-40.
22. Peyron C, Faraco, J, Rogers W. Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-97.
23. American Academy of Sleep Medicine, Diagnostic Classifcation Steering Committee. Te International Classifcation of Sleep Disorders, 2nd edition revised (ICSD). Westchester, IL: American Academy of Sleep Medicine; 2005.
24. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res 2010; 1314: 74-90.
25. Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/ orexin defciency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011; 21: 897-903.
26. Sakurai T. Orexin defciency and narcolepsy. Curr Opin Neurobiol 2013; 23: 760-6.
27. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004; 101: 4649-54.
28. Bernardis LL, Bellinger LL. Te lateral hypothalamic area revisited: ingestive behaviour. Neurosci Biobehav Rev 1996; 20: 189-287.
29. Haynes A, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, et al. Efects of single and chronic intracerebro-ventricular administration of the orexin on feeding in the rat. Peptides 1999; 20: 1099-105.
30. Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A, et al. Diferential efects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol Behav 2004; 81: 129-40.
31. Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A, et al. Anorexia and weight loss in male rats 24 h following single dose treatment with orexin-1 receptor antagonist SB-334867. Behav Brain Res 2005; 157: 331-41.
32. Sakurai T. Orexin system and feeding behaviour. In Nishino S, Sakurai T, eds. Te orexin/hypocretin system. Physiology and pathophysiology. Totowa, NJ: Humana Press; 2006. p. 99-106.
33. Rodgers RJ, Halford JCG, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JRS, et al. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic efect of orexin-A in rats. Eur J Neurosci 2001; 13: 1444-52.
34. Yamanaka A, Tsunematsu T. New approaches for the study of orexin function. J Neuroendocrinol 2010; 22: 818-24.
35. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisaka M, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 2000; 873: 181-7.
36. Mieda M, Williams SC, Sinton CM, Richardson JA, Sakurai T, Yanagisawa M. Orexin neurons function in an eferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. J Neurosci 2004; 24: 10493-501.
37. Boutrel B, Cannella N, De Lecea L. Te role of hypocretin in driving arousal and goal-oriented behaviours. Brain Res 2010; 1314: 103-11.
38. Torpe AJ, Kotz CM. Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. Brain Res 2005; 1050: 156-62.
39. Boutrel B, De Lecea L. Addiction and arousal: the hypocretin connection. Physiol Behav 2008; 93: 947-51.
40. Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci 2006; 29: 571-7.
41. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556-9.
42. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviours induced by morphine. J Neurosci 2006; 26: 398-405.
43. Borgland S, Chang SJ, Scott Bowers M, Tompson JL, Vittoz N, Floresco SB, et al. Orexin/Hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci 2009; 29: 11215-25.
44. Furudono Y, Ando C, Yamamoto C, Kobashi M, Yamamoto T. Involvement of specifc orexigenic neuropeptides in sweetener-induced overconsumption in rats. Behav Brain Res 2006; 175: 241-8.
45. Risco S, Mediavilla C. Efects of the selective orexin-1 receptor antagonist SB-334867-A on feeding and drinking behaviours and taste aversion learning. Behav Pharmacol 2009; 20: S95.
46. Cason AM, Smith RJ, Tahsli-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 2010; 100: 419-28.
47. Berthoud H. Metabolic and hedonic drives in the neural control of appetite: who is the boss? Curr Opin Neurobiol 2011; 21: 888-96.
48. Cooper SJ. Pharmacology of food, taste, and learned favour preferences. In Kirkhan TC, Cooper SJ, eds. Appetite and body weight. Integration system and the development of antiobesity drugs. Burlington, MA: Academic Press; 2007. p. 217-45.
49. Mediavilla C, Cabello V, Risco S. SB-334867-A, a selective orexin-1 receptor antagonist, enhances taste aversion learning and blocks taste preference learning in rats. Pharmacol Biochem Behav 2011; 98: 385-91.
50. Kenny PJ. Reward mechanisms in obesity: new insights and future directions. Neuron 2011; 69: 664-79.
51. Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009; 61: 162-76.
52. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 2002; 36: 229-40.
53. Sharf R, Sarhan M, Dileone RJ. Role of orexin/hypocretin in dependence and addiction. Brain Res 2010; 1314: 130-8.
54. Georgescu D, Zachariou V, Barrot M, Mieda M., Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 2003; 23: 3106-11.
55. Harris GC, Wimmer M, Randall-Tompson JF, Aston-Jones G. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res 2007; 176: 251-8.
56. Jupp B, Krivdic B, Krstew E, Lawrence AJ. Te orexin1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res 2011; 1391: 54-9.
57. Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci 2012; 35: 798-804.
58. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioural sensitization to cocaine. Neuron 2006; 49: 589-601.
59. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behaviour. Proc Natl Acad Sci U S A 2005; 102: 19168-73.
60. Saderi N, Escobar C, Salgado-Delgado R. La alteración de los ritmos biológicos causa enfermedades metabólicas y obesidad. Rev Neurol 2013; 57: 71-8.